Share price · PFE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PFE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026-2.2%
- 5 Oct 2026-1.4%
- 24 Jul 2026-1.9%
Nothing announced by PFE that day or the session before.
- 24 Jun 2026-2.8%
- 7 Apr 2026-2.6%
Nothing announced by PFE that day or the session before.
- 17 Mar 2026+3.2%
- 6 Mar 2026+1.7%
Nothing announced by PFE that day or the session before.
- 10 Feb 2026+2.1%
Nothing announced by PFE that day or the session before.
- 4 Feb 2026+3.9%
- 3 Feb 2026-3.3%
Share of unusual movement by asset
For each asset, the share of PFE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(95 total)
| Target & Modality | |||
|---|---|---|---|
abrocitinib(Cibinqo) | Approved | JAK1Small molecule | Atopic Dermatitis |
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | MEK1/2 and RAF (CRAF, BRAF) · FAKSmall molecule | Ovarian Cancer | |
| Approved | VEGFR1/2/3Small molecule | Renal Cell Carcinoma | |
| Approved | MEK1/2Small molecule | Non-Small Cell Lung CancerMelanoma | |
| Approved | Anti-CD30 antibody-drug conjugateAntibody–drug conjugate | Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma | |
brepocitinib(Lisraya) | Approved | TYK2/JAK1Small molecule | PsoriasisDermatomyositisNon-Infectious UveitisCutaneous SarcoidosisLichen PlanopilarisIdiopathic Inflammatory Myopathies |
crisaborole(Eucrisa) | Approved | PDE4Small molecule | Atopic Dermatitis |
| Approved | ALK, ROS1, MET/HGFR, and RONSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung Cancer | |
| Approved | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Approved | BRAF V600ESmall molecule | Non-Small Cell Lung CancerColorectal CancerMelanoma Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer | |
| Approved | Nectin-4Antibody–drug conjugate | Non-Small Cell Lung CancerBladder Cancer | |
| Approved | Topoisomerase II / DNASmall molecule | Breast Cancer | |
Ertugliflozin(Steglatro) | Approved | SGLT2Small molecule | Type 2 Diabetes |
Discontinued programmes (10)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
- ClesacostatDiscontinued · 2025-11
- IdrebormilastDiscontinued
- MaplirpaceptDiscontinued · 2026-02
- PF-05221304 + PF-06865571Discontinued · 2025-11
- PF-07868489Discontinued · 2026-10
- Propranolol (Inderal)Discontinued · 2022-03-04
- Sumatriptan Succinate Auto-Injector (Alsuma)Discontinued
- TanezumabDiscontinued · 2021-10
- TinlorafenibDiscontinued
- Voxelotor (Oxbryta)Discontinued · 2024-09-25
Upcoming events
(125 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (12)
November 2026 (1)
What to watch
December 2026 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (36)
January 2027 (2)
February 2027 (4)
What to watch
What to watch
What to watch
What to watch
March 2027 (5)
April 2027 (2)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (2)
August 2027 (3)
What to watch
What to watch
What to watch
September 2027 (4)
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (2)
What to watch
What to watch
December 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (35)
January 2028 (2)
February 2028 (3)
March 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (2)
May 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
June 2028 (4)
What to watch
What to watch
What to watch
What to watch
July 2028 (1)
What to watch
August 2028 (2)
What to watch
What to watch
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (3)
December 2028 (3)
What to watch
What to watch
What to watch
2029 (22)
January 2029 (2)
February 2029 (2)
What to watch
March 2029 (4)
What to watch
What to watch
What to watch
April 2029 (1)
What to watch
June 2029 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2029 (1)
What to watch
August 2029 (1)
What to watch
October 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (12)
February 2030 (2)
What to watch
What to watch
March 2030 (2)
May 2030 (1)
What to watch
June 2030 (2)
July 2030 (2)
What to watch
September 2030 (1)
What to watch
2031 (2)
July 2031 (2)
What to watch
What to watch
2032 (3)
February 2032 (1)
What to watch
April 2032 (1)
What to watch
2033 (2)
2034 (1)
April 2034 (1)
What to watch
Regulatory and conference events
(42)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 40 past events are shown.
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $16.6B | $3.0B | $1.9B+ $9.1B short-term inv. | —$5.4B operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $15.0B | $2.8B | $1.0B+ $7.3B short-term inv. | $248M$835M operating cash flow | report ↗ |
| 2026-Q1 | $14.5B | $2.5B | —+ $8.2B short-term inv. | —$2.6B operating cash flow | report ↗ |
| 2025-Q4 | $17.6B | $3.2B | $13.6B | — | report ↗ |
| 2025-Q3 | $16.7B | $2.5B | $15.0B+ $10.1B short-term inv. | —$4.6B operating cash flow | report ↗ |
| 2025-Q2 | $14.7B | $2.5B | $13.2B+ $9.5B short-term inv. | —-$582M operating cash flow | report ↗ |
| 2025-Q1 | $13.7B | $2.2B | $17.3B+ $14.0B short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2024-Q4 | $17.8B | $3.0B | $20.5B | — | report ↗ |
| 2024-Q3 | $17.7B | $2.6B | $10.0B+ $6.8B short-term inv. | —$6.7B operating cash flow | report ↗ |
| 2024-Q2 | $13.3B | $2.7B | $7.1B+ $4.4B short-term inv. | —-$1.8B operating cash flow | report ↗ |
| 2024-Q1 | $14.9B | $2.5B | $780M+ $8.2B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2023-Q4 | $13.2B | $2.7B | $3.2B+ $26.2B short-term inv. | $2.4B$3.5B operating cash flow | report ↗ |
| 2023-Q3 | $12.7B | $2.6B | $2.7B+ $24.1B short-term inv. | —-$1.2B operating cash flow | report ↗ |
| 2023-Q2 | $18.3B | $2.5B | $2.2B+ $16.1B short-term inv. | —$1.2B operating cash flow | report ↗ |
| 2022-Q4 | $22.6B | $2.7B | $1.3B+ $20.2B short-term inv. | —$6.0B operating cash flow | report ↗ |
| 2022-Q3 | $27.7B | $2.8B | $1.8B+ $25.6B short-term inv. | —$8.2B operating cash flow | report ↗ |
| 2022-Q2 | $25.7B | $2.3B | $2.5B+ $17.3B short-term inv. | —$6.5B operating cash flow | report ↗ |
| 2021-Q4 | — | $3.4B | $2.0B+ $27.7B short-term inv. | —$10.8B operating cash flow | report ↗ |
| 2021-Q3 | — | $2.5B | $2.4B+ $19.3B short-term inv. | —$11.3B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $62.6B | $10.4B | $13.6B+ $9.2B short-term inv. | —$11.7B operating cash flow | report ↗ |
Pfizer reported full-year 2025 revenue of $62,579M, down 2% YoY, with R&D spend of $10,437M, down 4% YoY. Cash and equivalents were $13,596M, and net income was $7,771M, down 3% YoY.
The company reaffirmed full-year 2026 guidance, including revenues of $59.5–62.5 billion and adjusted diluted EPS of $2.80–3.00. Key developments included completion of the Metsera acquisition, a global GLP-1 collaboration with YaoPharma, and an agreement to exit its ViiV Healthcare stake for $1.875 billion. Clinical highlights featured positive Phase 3 results for Braftovi, Hympavzi, Padcev, and Tukysa, plus positive Phase 2b results for the ultra-long-acting GLP-1 candidate PF-3944; Pfizer plans approximately 20 key pivotal study starts in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $63.6B | $10.8B | $20.5B+ $10.9B short-term inv. | —$12.7B operating cash flow | report ↗ |
| 2023-FY | $58.5B | $10.7B | $12.7B+ $4.4B short-term inv. | —$8.7B operating cash flow | report ↗ |
| 2022-FY | $100.3B | $11.4B | $468M+ $18.7B short-term inv. | —$29.3B operating cash flow | report ↗ |
| 2021-FY | $81.3B | $13.8B | $2.0B+ $22.0B short-term inv. | —$32.6B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($3.0M), 2 sales ($135K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | BOURLA ALBERT · director, Chairman & CEO | Award / grant (derivative) | 21 | $28.89 | $607 | Form 4 |
| 2026-10-30 | BOURLA ALBERT · director, Chairman & CEO | Award / grant (derivative) | 20 | $30.52 | $610 | Form 4 |
| 2026-10-15 | BOURLA ALBERT · director, Chairman & CEO | Award / grant (derivative) | 20 | $29.44 | $589 | Form 4 |
| 2026-10-13 | BOURLA ALBERT · director, Chairman & CEO | Award / grant (derivative) | 71 | $28.37 | $2K | Form 4 |
| 2026-09-30 | BOURLA ALBERT · director, Chairman & CEO | Award / grant (derivative) | 21 | $28.52 | $599 | Form 4 |
| 2026-09-25 | Taraporevala Cyrus · director | Award / grant (derivative) | 1,307.987 | $28.67 | $37K | Form 4 |
| 2026-09-25 | SMITH JAMES C · director | Award / grant (derivative) | 1,569.585 | $28.67 | $45K | Form 4 |
| 2026-09-25 | Quincey James · director | Award / grant (derivative) | 1,351.587 | $28.67 | $39K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,912 reporting institutions held 3741.5M shares ($101.1B, 65.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 498,257,550 | $14.0B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 369,430,012 | $10.4B |
| 3 | STATE STREET CORP | 301,589,865 | $8.5B |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 133,561,742 | $3.7B |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 116,734,695 | $3.3B |
| 6 | Fisher Asset Management, LLC | 104,964,427 | $2.9B |
| 7 | MORGAN STANLEY | 92,685,370 | $2.6B |
| 8 | NORTHERN TRUST CORP | 62,026,552 | $1.7B |
| 9 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 56,911,830 | $1.6B |
| 10 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 54,508,560 | $1.5B |
| 11 | Bank of New York Mellon Corp | 53,879,900 | $1.5B |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 51,891,636 | $1.5B |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 49,916,961 | $1.4B |
| 14 | GOLDMAN SACHS GROUP INC | 47,105,556 | $1.3B |
| 15 | BANK OF AMERICA CORP /DE/ | 46,545,479 | $1.3B |